Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02937142
Other study ID # 2015/2115
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2017
Est. completion date October 2020

Study information

Verified date December 2021
Source St. Olavs Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder which starts in childhood and is characterized by symptoms of attention deficit, hyperactivity and impulsivity. Persistence into adolescence is frequently associated with among other low educational achievement, interpersonal difficulties, anxious and depressive symptoms and sleep problems. Treatment guidelines recommend psychological treatment as part of the treatment plan, however compared to children and adults, there is still a substantial lack of knowledge about appropriate psychological treatment in adolescents. The present study examines a psychological intervention for adolescents with ADHD, cognitive behavior group therapy. The intervention consists of 12 weekly cognitive behavioral therapy sessions addressing core difficulties and concerns of the adolescent population with ADHD. The investigators wish to determine the efficacy of group therapy in adolescents with ADHD who receive medical treatment but still have impairing ADHD symptoms.


Description:

Change February 1st 2017: Inclusion of patients with mild to moderate behavioral problems in order to achieve enough participants in the study. Change February 1st 2017: The study primarily recruits patients who are on pharmacological treatment for ADHD. However, for ethical reasons and in order to achieve enough participants, the study will also recruit patients who have not responded to at least two drug trials or have been unable to continue pharmacological treatment because of intolerable side effects. Change February 1st 2018: The Weiss Functional Impairment Rating Scale, Rosenberg and BRIEF questionnaires will not be collected at the 9-month follow-up due to lack of resources (project assistance).


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date October 2020
Est. primary completion date January 2020
Accepts healthy volunteers No
Gender All
Age group 14 Years to 18 Years
Eligibility Inclusion Criteria: - Attention deficit hyperactivity disorder (ICD-10) - Clinical Global Impression (CGI) >=3 - Informed consent patient - informed consent parents - if on medication, dosage is stable since at least 2 months Exclusion Criteria: - mental retardation - behavioral problems - drug addiction - psychosis - suicidal

Study Design


Related Conditions & MeSH terms

  • Attention Deficit Disorder With Hyperactivity
  • Hyperkinesis

Intervention

Behavioral:
cognitive behavior group therapy
1,5 hours weekly session during 12 weeks, 8 participants, 2 therapists.
Other:
Treatment as usual
Education on ADHD, and ADHD medication if indicated

Locations

Country Name City State
Norway Barne- og ungdomspsykiatrisk poliklinikk, St Olavs Hospital Trondheim

Sponsors (2)

Lead Sponsor Collaborator
St. Olavs Hospital Norwegian University of Science and Technology

Country where clinical trial is conducted

Norway, 

References & Publications (1)

Nøvik TS, Haugan AJ, Lydersen S, Thomsen PH, Young S, Sund AM. Cognitive-behavioural group therapy for adolescents with ADHD: study protocol for a randomised controlled trial. BMJ Open. 2020 Mar 25;10(3):e032839. doi: 10.1136/bmjopen-2019-032839. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary ADHD-Rating Scale (ADHD-RS) interview 12 weeks (at baseline and immediately after the last group therapy session)
Secondary ADHD-Rating Scale (ADHD-RS) 9 months
Secondary Clinical Global Impression (CGI) 12 weeks (at baseline and immediately after the last group therapy session)
Secondary Weiss Functional Impairment Rating Scale (WFIRS) 12 weeks (at baseline and immediately after the last group therapy session)
Secondary Weiss Functional Impairment Rating Scale (WFIRS) 9 months
Secondary Children's Global Assessment Scale (CGAS) 9 months
Secondary Anxiety symptoms (SCARED) 12 weeks (at baseline and immediately after the last group therapy session)
Secondary Depressive symptoms (Mood and Feelings Questionnaire (MFQ) Norwegian version "Humøret ditt") 12 weeks (at baseline and immediately after the last group therapy session)
Secondary Sleep problems (Adolescent Sleep Wake Scale 12 weeks (at baseline and immediately after the last group therapy session)
Secondary Self-esteem (Rosenberg Self-Esteem Scale) 12 weeks (at baseline and immediately after the last group therapy session)
Secondary Self-esteem (Rosenberg Self-Esteem Scale) 9 months
Secondary Self-efficacy (General Perceived Self-Efficacy Scale) 12 weeks (at baseline and immediately after the last group therapy session)
Secondary Self-efficacy (General Perceived Self-Efficacy Scale) 9 months
Secondary Executive functioning (Behavior Rating Scale of Executive Functioning, BRIEF) 12 weeks (at baseline and immediately after the last group therapy session)
Secondary Executive functioning (Behavior Rating Scale of Executive Functioning, BRIEF) 9 months
Secondary ASEBA Brief Problem Monitor 9 months
See also
  Status Clinical Trial Phase
Completed NCT00202605 - Safety and Efficacy of SPD465 in Adults With ADHD Phase 2
Not yet recruiting NCT02677519 - A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD Phase 4
Completed NCT02730572 - Concerta (Methylphenidate) -To-Generic Switch Study N/A
Completed NCT01681082 - Psychological Effects of Tai Chi Training N/A
Active, not recruiting NCT01330693 - Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy Phase 3
Completed NCT00830700 - Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study N/A
Completed NCT01012622 - An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD) Phase 4
Completed NCT00626236 - Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems Phase 2
Completed NCT00598182 - Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study N/A
Completed NCT00381407 - Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder N/A
Completed NCT00247572 - Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Phase 2
Completed NCT00178503 - Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children Phase 2/Phase 3
Completed NCT00118911 - Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder N/A
Completed NCT00557011 - NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD Phase 2
Completed NCT00218322 - Effectiveness of ATMX in Treating Adolescents With ADHD and SUD Phase 4
Completed NCT00071656 - Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I N/A
Active, not recruiting NCT00057668 - Preventing Behavior Problems in Children With ADHD Phase 2
Completed NCT00050622 - Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD) N/A
Completed NCT00050050 - Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder Phase 1
Completed NCT00031395 - Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children Phase 3

External Links